tiprankstipranks
Crispr Therapeutics (CH:1CG)
NASDAQ:1CG
Switzerland Market
1CG
Crispr Therapeutics AG
RESEARCH TOOLSreports

Crispr Therapeutics AG (1CG) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

1CG Analyst Ratings

Moderate Buy
14Ratings
Moderate Buy
9 Buy
5 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Crispr
Therapeutics AG
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1CG Stock 12 Month Forecast

Average Price Target

$59.81
Based on 14 Wall Street analysts offering 12 month price targets for Crispr Therapeutics AG in the last 3 months. The average price target is $59.81 with a high forecast of $89.09 and a low forecast of $36.45. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"35":"$35","90":"$90","48.75":"$48.8","62.5":"$62.5","76.25":"$76.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":89.0901066,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$89.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":59.808742892307684,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$59.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.4459527,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$36.45</span>\n  </div></div>","useHTML":true}}],"tickPositions":[35,48.75,62.5,76.25,90],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.051,48.438623584615385,51.82624716923077,55.21387075384615,58.601494338461535,61.98911792307692,65.37674150769232,68.76436509230768,72.15198867692308,75.53961226153845,78.92723584615385,82.31485943076922,85.70248301538462,{"y":89.0901066,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.051,46.186210991715974,47.321421983431954,48.456632975147926,49.591843966863905,50.72705495857988,51.86226595029586,52.99747694201183,54.13268793372781,55.26789892544378,56.40310991715976,57.53832090887573,58.67353190059171,{"y":59.808742892307684,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.051,44.389073284615385,43.72714656923077,43.06521985384615,42.40329313846154,41.741366423076926,41.07943970769231,40.41751299230769,39.755586276923076,39.09365956153846,38.43173284615385,37.76980613076923,37.107879415384616,{"y":36.4459527,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":45.051,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.051,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.051,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.051,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.051,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.051,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.051,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.051,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.051,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.051,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.051,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.051,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.051,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$89.09Average Price Target$59.81Lowest Price Target$36.45
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on CH:1CG
Gil Blum
Needham
Needham
CHF66.41
Buy
―
Reiterated
06/24/26
Gil Blum Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target on Pipeline Upside and 2026 Data Catalysts
Morgan Stanley Analyst forecast on CH:1CG
Maxwell Skor
Morgan Stanley
Morgan Stanley
CHF48.59
Hold
―
Upgraded
06/11/26
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (NASDAQ: CRSP) and Hinge Health, Inc. Class A (NYSE: HNGE)
Mizuho Securities Analyst forecast on CH:1CG
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
CHF68.84
Buy
―
Reiterated
06/10/26
Crispr Therapeutics AG (CRSP) Gets a Buy from Mizuho Securities
William Blair Analyst forecast on CH:1CG
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
06/04/26
Analysts Are Bullish on Top Healthcare Stocks: Insulet (PODD), Crispr Therapeutics AG (CRSP)
Bank of America Securities Analyst forecast on CH:1CG
Alec Stranahan
Bank of America Securities
Bank of America Securities
CHF67.22
Buy
―
Reiterated
05/13/26
Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Caris Life Sciences, Inc. (CAI)
Bernstein Analyst forecast on CH:1CG
William Pickering
Bernstein
Bernstein
CHF40.5→CHF45.35
Hold
―
Assigned
05/13/26
Crispr Therapeutics price target raised to $56 from $50 at BernsteinCrispr Therapeutics price target raised to $56 from $50 at Bernstein
Evercore ISI Analyst forecast on CH:1CG
Jonathan Miller
Evercore ISI
Evercore ISI
CHF59.93→CHF61.55
Buy
―
Reiterated
05/11/26
Crispr Therapeutics price target raised to $76 from $74 at Evercore ISICrispr Therapeutics price target raised to $76 from $74 at Evercore ISI
Citi Analyst forecast on CH:1CG
Yigal Nochomovitz
Citi
Citi
CHF64.79→CHF66.41
Buy
―
Assigned
05/06/26
Crispr Therapeutics price target raised to $82 from $80 at CitiCrispr Therapeutics price target raised to $82 from $80 at Citi
H.C. Wainwright Analyst forecast on CH:1CG
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
CHF64.79
Buy
―
Reiterated
05/05/26
CRISPR Therapeutics: Pipeline Expansion and In Vivo CAR-T Platform Support Buy Rating; $80 Price Target Reiterated
Wells Fargo Analyst forecast on CH:1CG
Yanan Zhu
Wells Fargo
Wells Fargo
CHF60.74
Hold
―
Reiterated
05/05/26
Analysts Conflicted on These Healthcare Names: Dexcom (NASDAQ: DXCM), Ironwood Pharma (NASDAQ: IRWD) and Crispr Therapeutics AG (NASDAQ: CRSP)
Piper Sandler Analyst forecast on CH:1CG
Edward Tenthoff
Piper Sandler
Piper Sandler
CHF89.09
Buy
―
Reiterated
05/05/26
Crispr Therapeutics AG (CRSP) Gets a Buy from Piper Sandler
TD Cowen Analyst forecast on CH:1CG
Tyler Van Buren
TD Cowen
TD Cowen
CHF36.45
Hold
―
Reiterated
05/04/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: GeneDx Holdings (NASDAQ: WGS) and Crispr Therapeutics AG (NASDAQ: CRSP)
Chardan Capital Analyst forecast on CH:1CG
Geulah Livshits
Chardan Capital
Chardan Capital
CHF61.55
Buy
―
Reiterated
05/04/26
Chardan Capital Remains a Buy on Crispr Therapeutics AG (CRSP)
RBC Capital Analyst forecast on CH:1CG
Luca Issi
RBC Capital
RBC Capital
CHF40.5
Hold
―
Reiterated
05/04/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: ADC Therapeutics (NYSE: ADCT), Crispr Therapeutics AG (NASDAQ: CRSP) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Truist Financial Analyst forecast on CH:1CG
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
03/02/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Kyntra Bio (NASDAQ: KYNB), Crispr Therapeutics AG (NASDAQ: CRSP) and GoodRx Holdings (NASDAQ: GDRX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on CH:1CG
Gil Blum
Needham
Needham
CHF66.41
Buy
―
Reiterated
06/24/26
Gil Blum Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target on Pipeline Upside and 2026 Data Catalysts
Morgan Stanley Analyst forecast on CH:1CG
Maxwell Skor
Morgan Stanley
Morgan Stanley
CHF48.59
Hold
―
Upgraded
06/11/26
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (NASDAQ: CRSP) and Hinge Health, Inc. Class A (NYSE: HNGE)
Mizuho Securities Analyst forecast on CH:1CG
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
CHF68.84
Buy
―
Reiterated
06/10/26
Crispr Therapeutics AG (CRSP) Gets a Buy from Mizuho Securities
William Blair Analyst forecast on CH:1CG
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
06/04/26
Analysts Are Bullish on Top Healthcare Stocks: Insulet (PODD), Crispr Therapeutics AG (CRSP)
Bank of America Securities Analyst forecast on CH:1CG
Alec Stranahan
Bank of America Securities
Bank of America Securities
CHF67.22
Buy
―
Reiterated
05/13/26
Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Caris Life Sciences, Inc. (CAI)
Bernstein Analyst forecast on CH:1CG
William Pickering
Bernstein
Bernstein
CHF40.5→CHF45.35
Hold
―
Assigned
05/13/26
Crispr Therapeutics price target raised to $56 from $50 at BernsteinCrispr Therapeutics price target raised to $56 from $50 at Bernstein
Evercore ISI Analyst forecast on CH:1CG
Jonathan Miller
Evercore ISI
Evercore ISI
CHF59.93→CHF61.55
Buy
―
Reiterated
05/11/26
Crispr Therapeutics price target raised to $76 from $74 at Evercore ISICrispr Therapeutics price target raised to $76 from $74 at Evercore ISI
Citi Analyst forecast on CH:1CG
Yigal Nochomovitz
Citi
Citi
CHF64.79→CHF66.41
Buy
―
Assigned
05/06/26
Crispr Therapeutics price target raised to $82 from $80 at CitiCrispr Therapeutics price target raised to $82 from $80 at Citi
H.C. Wainwright Analyst forecast on CH:1CG
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
CHF64.79
Buy
―
Reiterated
05/05/26
CRISPR Therapeutics: Pipeline Expansion and In Vivo CAR-T Platform Support Buy Rating; $80 Price Target Reiterated
Wells Fargo Analyst forecast on CH:1CG
Yanan Zhu
Wells Fargo
Wells Fargo
CHF60.74
Hold
―
Reiterated
05/05/26
Analysts Conflicted on These Healthcare Names: Dexcom (NASDAQ: DXCM), Ironwood Pharma (NASDAQ: IRWD) and Crispr Therapeutics AG (NASDAQ: CRSP)
Piper Sandler Analyst forecast on CH:1CG
Edward Tenthoff
Piper Sandler
Piper Sandler
CHF89.09
Buy
―
Reiterated
05/05/26
Crispr Therapeutics AG (CRSP) Gets a Buy from Piper Sandler
TD Cowen Analyst forecast on CH:1CG
Tyler Van Buren
TD Cowen
TD Cowen
CHF36.45
Hold
―
Reiterated
05/04/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: GeneDx Holdings (NASDAQ: WGS) and Crispr Therapeutics AG (NASDAQ: CRSP)
Chardan Capital Analyst forecast on CH:1CG
Geulah Livshits
Chardan Capital
Chardan Capital
CHF61.55
Buy
―
Reiterated
05/04/26
Chardan Capital Remains a Buy on Crispr Therapeutics AG (CRSP)
RBC Capital Analyst forecast on CH:1CG
Luca Issi
RBC Capital
RBC Capital
CHF40.5
Hold
―
Reiterated
05/04/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: ADC Therapeutics (NYSE: ADCT), Crispr Therapeutics AG (NASDAQ: CRSP) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Truist Financial Analyst forecast on CH:1CG
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
03/02/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Kyntra Bio (NASDAQ: KYNB), Crispr Therapeutics AG (NASDAQ: CRSP) and GoodRx Holdings (NASDAQ: GDRX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Crispr Therapeutics AG

3 Months
Mani ForooharLeerink Partners
Success Rate
13/22 ratings generated profit
59%
Average Return
+7.56%
Copying Mani Foroohar's trades and holding each position for 3 Months would result in 59.09% of your transactions generating a profit, with an average return of +7.56% per trade.
1 Year
Mani ForooharLeerink Partners
Success Rate
11/22 ratings generated profit
50%
Average Return
+7.39%
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +7.39% per trade.
2 Years
Mani ForooharLeerink Partners
Success Rate
11/22 ratings generated profit
50%
Average Return
+2.38%
Copying Mani Foroohar's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +2.38% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1CG Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
13
12
9
9
9
Buy
9
7
6
6
6
Hold
6
6
3
5
5
Sell
1
1
1
0
0
Strong Sell
0
0
0
0
0
total
29
26
19
20
20
In the current month, 1CG has received 15 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. 1CG average Analyst price target in the past 3 months is 59.81.
Each month's total comprises the sum of three months' worth of ratings.

1CG Financial Forecast

1CG Earnings Forecast

Next quarter’s earnings estimate for 1CG is -$0.95 with a range of -$1.15 to -$0.64. The previous quarter’s EPS was -$1.02. 1CG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 1CG has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1CG is -$0.95 with a range of -$1.15 to -$0.64. The previous quarter’s EPS was -$1.02. 1CG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 1CG has Performed in-line its overall industry.

1CG Sales Forecast

Next quarter’s sales forecast for 1CG is $5.66M with a range of $0.00 to $24.92M. The previous quarter’s sales results were $1.16M. 1CG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 1CG has Performed in-line its overall industry.
Next quarter’s sales forecast for 1CG is $5.66M with a range of $0.00 to $24.92M. The previous quarter’s sales results were $1.16M. 1CG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 1CG has Performed in-line its overall industry.

1CG Stock Forecast FAQ

What is CH:1CG’s average 12-month price target, according to analysts?
Based on analyst ratings, Crispr Therapeutics’s 12-month average price target is 59.81.
    What is CH:1CG’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:1CG, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Crispr Therapeutics a Buy, Sell or Hold?
        Crispr Therapeutics has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 5 hold ratings and 0 sell ratings.
          What is Crispr Therapeutics’s share price target?
          The average share price target for Crispr Therapeutics is 59.81. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $89.09 ,and the lowest forecast is $36.45. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Crispr Therapeutics?
            Crispr Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
              How can I buy shares of Crispr Therapeutics?
              To buy shares of CH:1CG, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.